BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34625931)

  • 1. [Clinical characteristics and therapeutic effect of TP53 variant in patients with acute leukemia].
    Mi R; Guo Z; Liu W; Hu J; Fan R; Chen L; Liu J; Wei X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Oct; 38(10):955-960. PubMed ID: 34625931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
    Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
    Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia].
    Zhang Y; Hu XX; Gao L; Ni X; Chen J; Chen L; Zhang WP; Yang JM; Wang JM
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):932-938. PubMed ID: 31856443
    [No Abstract]   [Full Text] [Related]  

  • 5. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
    Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of
    Liu H; Shi Y; Tao S; Li Y; Wang C; Yu L
    Hematology; 2023 Dec; 28(1):2223866. PubMed ID: 37313982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
    Yoshida S; Onozawa M; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Mori A; Hidaka D; Minauchi K; Shigematsu A; Hashiguchi J; Igarashi T; Kakinoki Y; Tsutsumi Y; Ibata M; Kobayashi H; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Ota S; Kondo T; Teshima T
    Int J Hematol; 2023 Apr; 117(4):544-552. PubMed ID: 36572814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype.
    Warnstorf D; Bawadi R; Schienke A; Strasser R; Schmidt G; Illig T; Tauscher M; Thol F; Heuser M; Steinemann D; Davenport C; Schlegelberger B; Behrens YL; Göhring G
    Genes Chromosomes Cancer; 2021 Jun; 60(6):452-457. PubMed ID: 33486841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
    Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
    Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.
    Loke J; Labopin M; Craddock C; Cornelissen JJ; Labussière-Wallet H; Wagner-Drouet EM; Van Gorkom G; Schaap NPM; Kröger NM; Veelken JH; Rovira M; Menard AL; Bug G; Bazarbachi A; Giebel S; Brissot E; Nagler A; Esteve J; Mohty M
    Cancer; 2022 Aug; 128(15):2922-2931. PubMed ID: 35612815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
    Rücker FG; Schlenk RF; Bullinger L; Kayser S; Teleanu V; Kett H; Habdank M; Kugler CM; Holzmann K; Gaidzik VI; Paschka P; Held G; von Lilienfeld-Toal M; Lübbert M; Fröhling S; Zenz T; Krauter J; Schlegelberger B; Ganser A; Lichter P; Döhner K; Döhner H
    Blood; 2012 Mar; 119(9):2114-21. PubMed ID: 22186996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
    Zeichner SB; Alghamdi S; Elhammady G; Poppiti RJ
    Asian Pac J Cancer Prev; 2014; 15(4):1603-9. PubMed ID: 24641375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
    Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
    Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
    Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and experimental characteristics of 20 patients with acute myeloid leukemia with complex variant of t(8; 21)].
    Xia J; Chen SN; Pan JL; Wang QR; Wu YF; Wang Y; Zhang J; Shen J; Xue YQ; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):815-20. PubMed ID: 23998566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
    Leung GMK; Zhang C; Ng NKL; Yang N; Lam SSY; Au CH; Chan TL; Ma ESK; Tsui SP; Ip HW; So JCC; Ng MHL; Cheng KCK; Wong KF; Siu LLP; Yip SF; Lin SY; Lau JSM; Luk TH; Lee HKK; Lau CK; Kho B; Kwong YL; Leung AYH
    Am J Hematol; 2019 Jun; 94(6):650-657. PubMed ID: 30900772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
    Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
    Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.